非小细胞肺癌患者对术后辅助化疗的评价和选择

[目的]了解已接受术后辅助化疗的非小细胞肺癌（NSCLC）患者对辅助化疗的评价和选择倾向。[方法]调查2006年11月1日-2009年3月31日间接受术后辅助化疗的NSCLC60例。调查内容包括患者对辅助化疗的评价，患者在假设病理ⅠB期、Ⅱ期和Ⅲ A期条件下可接受辅助化疗带来的最小生存率和中位生存期。[结果]93.3％患者认为辅助化疗值得做。约70％患者愿意接受辅助化疗以获得生存期延长1年或者5年生存率提高10％。曾出现化疗重度毒副反应、Ⅲ A期和经济状况差的患者要求辅助化疗带来的生存获益更高。[结论]多数患者能够接受术后辅助化疗带来的益处和毒性反应．

Patients' Evaluation and Preference for Adjuvant Chemotherapy in Non-small Cell Lung Caner

[Purpose] To investigate the patients＇ evaluation and preference for adjuvant chemotherapy in completely resected patients with non-small cell lung cancer（NSCLC）. [Methods ] Sixty consecutive NSCLC patients from November 1, 2006 to March 31, 2009, who received adjuvant chemotherapy were investigated. The survey questions included the patient＇s evaluate and preferences of adjuvant chemotherapy. Patients were hypothetical categorized as pathological stage Ⅰ B,Ⅱ and Ⅲ A,then presented with hypothetical scenarios based on known median survival time and survival rates without adjuvant chemotherapy. [Results] Most of the patients （93.3%） consider adjuvant chemotherapy were worthwhile. 70% of them considered that an additional 12 months in survival time or 10% in survival rates were judged sufficient to make adjuvant chemotherapy worthwhile. The patients experience serious adverse effects, stage Ⅲ A and worse economic status were the factors that influence the patients ask for higher benefit. [Conclusion] Most of the patients can accept the benefits and toxicities from adjuvant chemotherapy.